Neuroscientific Biopharmaceuticals: Half Yearly Report and Accounts
Filed with ASX · · 24 pages · English
The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report. 5. Attachments The Interim financial report of NeuroScientific Biopharmaceuticals Limited for the half-year ended 31 December 2025 is attached. 6. Signed Signed ___________________________ Mr Rob McKenzie Chairman 25 February 2026 CORPORATE DIRECTORY DIRECTORS Mr Rober
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Quarterly Activities/Appendix 4C Cash Flow Report
- Successful Clinical Results Achieved under Special Access
- Trading Halt
- Fourth Patient Commences StemSmart MSC Treatment
- 2025 Annual Report & Appendix 4E
Later from Neuroscientific Biopharmaceuticals
- Remarkable Results from Patients treated with StemSmart
- 2026 Annual Report & Appendix 4E
- Leading CRO Appointed for Phase 2 Crohn's Trial
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals